Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.

Literature DB >> 1906386

A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.

Abstract

Prostaglandins have been implicated in the immune suppression associated with the development of some tumours. Application of the prostaglandin synthetase inhibitor indomethacin, to murine skin prior to treatment with the chemical carcinogens benzo(a)pyrene (BP) or 7,12 dimethylbenz(a)anthracene (DMBA), restored contact sensitivity responses to 2,4-dinitrofluorobenzene in BP- but not DMBA-treated mice. However, indomethacin failed to restore antibody responses in either group of mice. Prolonged treatment with BP or DMBA led to cutaneous tumour formation. Indomethacin was found to delay the onset and reduce the size of tumours in BP- but not DMBA-treated mice. It is proposed that prostaglandin-induced suppression of cellular cutaneous immunity may play a role in BP- but not DMBA-induced cutaneous carcinogenesis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1991 PMID： 1906386 PMCID： PMC1535727 DOI： 10.1111/j.1365-2249.1991.tb05674.x

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

21 in total

1. Effect of indomethacin in inhibition of DMBA chemical carcinogenesis.

Authors: A R Mohammad; K A Sastry; A Ruprecht; J E Turner; M Batarfi; R Khalifa
Journal: J Oral Med Date: 1986 Jul-Sep

2. Modulation of the population density of identifiable epidermal Langerhans cells associated with enhancement or suppression of cutaneous immune reactivity.

Authors: L A Rheins; J J Nordlund
Journal: J Immunol Date: 1986-02-01 Impact factor: 5.422

3. Indomethacin inhibits the chemical carcinogen benzo(a)pyrene but not dimethylbenz(a)anthracene from altering Langerhans cell distribution and morphology.

Authors: F J Andrews; G M Halliday; C K Narkowicz; H K Muller
Journal: Br J Dermatol Date: 1991-01 Impact factor: 9.302

4. Sensitization through carcinogen-induced Langerhans cell-deficient skin activates specific long-lived suppressor cells for both cellular and humoral immunity.

Authors: G M Halliday; H K Muller
Journal: Cell Immunol Date: 1987-10-01 Impact factor: 4.868

5. Suppression of the cutaneous immune response following topical application of the prostaglandin PGE2.

Authors: L A Rheins; L Barnes; S Amornsiripanitch; C E Collins; J J Nordlund
Journal: Cell Immunol Date: 1987-04-15 Impact factor: 4.868

6. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern.

Authors: E E Vanderveen; R C Grekin; N A Swanson; K Kragballe
Journal: Arch Dermatol Date: 1986-04

7. Immunohistochemical detection of HIV structural proteins and distribution of T-lymphocytes and Langerhans cells in the oral mucosa of HIV infected patients.

Authors: J Becker; P Ulrich; R Kunze; H Gelderblom; A Langford; P Reichart
Journal: Virchows Arch A Pathol Anat Histopathol Date: 1988

8. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs.

Authors: T M el Attar; H S Lin
Journal: J Oral Pathol Date: 1987-11

A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.

1. Effect of indomethacin in inhibition of DMBA chemical carcinogenesis.

2. Modulation of the population density of identifiable epidermal Langerhans cells associated with enhancement or suppression of cutaneous immune reactivity.

3. Indomethacin inhibits the chemical carcinogen benzo(a)pyrene but not dimethylbenz(a)anthracene from altering Langerhans cell distribution and morphology.

4. Sensitization through carcinogen-induced Langerhans cell-deficient skin activates specific long-lived suppressor cells for both cellular and humoral immunity.

5. Suppression of the cutaneous immune response following topical application of the prostaglandin PGE2.

6. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern.

7. Immunohistochemical detection of HIV structural proteins and distribution of T-lymphocytes and Langerhans cells in the oral mucosa of HIV infected patients.

8. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs.

9. Induction of tolerance via skin depleted of Langerhans cells by a chemical carcinogen.

10. Mechanism of inhibition of tumour growth by aspirin and indomethacin.

1. Effects of systemic indomethacin on photocarcinogenesis in hairless mice.

2. Langerhans cell migration patterns from sheep skin following topical application of carcinogens.

3. Tobacco smoke condensate cutaneous carcinogenesis: changes in Langerhans' cells and tumour regression.